塞来昔布对T细胞淋巴瘤细胞增殖及侵袭功能的影响

doi:10.3969/j.issn.1004-616x.2016.04.002

癌变·畸变·突变 ›› 2016, Vol. 28 ›› Issue (4): 255-261.doi: 10.3969/j.issn.1004-616x.2016.04.002

塞来昔布对T细胞淋巴瘤细胞增殖及侵袭功能的影响

马鸣¹, 杨兴肖², 王雪晓³, 刘丽华³, 赵连梅³, 杜彦艳¹, 单保恩³

1. 河北医科大学第四医院检验科, 河北石家庄 050011;
2. 河北医科大学第四医院感染管理科, 河北石家庄 050011;
3. 河北医科大学第四医院科研中心, 河北石家庄 050011

收稿日期:2015-11-17 修回日期:2016-02-25 出版日期:2016-07-31 发布日期:2016-07-31
通讯作者: 单保恩,E-mail:shanbaoen@163.com E-mail:shanbaoen@163.com
作者简介:马鸣,E-mail:maming19830419@163.com
基金资助:
河北省卫生厅指令性课题（20150305）

Effects of celecoxib on proliferation and invasion of T cell lymphoma

MA Ming¹, YANG Xingxiao², WANG Xuexiao³, LIU Lihua³, ZHAO Lianmei³, DU Yanyan¹, SHAN Baoen³

1. Clinical Laboratory of the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011;
2. Department of Infection Management of the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011;
3. Research Center of the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei, China

Received:2015-11-17 Revised:2016-02-25 Online:2016-07-31 Published:2016-07-31

摘要/Abstract

摘要： 目的：研究塞来昔布对T细胞淋巴瘤细胞增殖、化疗敏感性及侵袭能力的影响，并探讨其作用机制。方法：分别用不同浓度（0、20、40及80μmol/L）塞来昔布处理T细胞淋巴瘤Jurkat和Hut78细胞系24、48和72 h后，采用MTT法检测Jurkat和Hut78细胞的增殖活性。再用40μmol/L塞来昔布处理Jurkat和Hut78细胞48 h后，采用MTT法检测其对化疗药物敏感性的影响；流式细胞术检测塞来昔布对Jurkat和Hut78细胞凋亡水平的影响；Transwell小室检测塞来昔布致Jurkat和Hut78细胞侵袭能力的变化；实时荧光定量PCR （qPCR）及Western blot技术分别从mRNA及蛋白水平检测塞来昔布对Jurkat和Hut78细胞系P38、P65、Bcl-2、Bax、MDR1、MMP2及MMP9表达水平的影响。结果：与对照组比较，20～80μmol/L塞来昔布作用于Jurkat和Hut78细胞不同时间后，细胞增殖活性均受到明显抑制（P<0.05）。40μmol/L塞来昔布对化疗药物的敏感性明显增强（P<0.05），且凋亡水平明显增加（P<0.01）；与40μmol/L塞来昔布共培养的Jurkat和Hut78细胞，其穿透Transwell小室的能力明显下降（P<0.01），且P38及Bax蛋白的表达水平均明显增加（P均<0.01），而P65、MDR1、Bcl-2、MMP2及MMP9表达水平均明显降低（P均<0.01）。结论：塞来昔布对T表型淋巴瘤细胞增殖和侵袭能力具有明显抑制作用，提示其在T细胞淋巴瘤的临床治疗中具有应用前景。

关键词: 塞来昔布, T细胞淋巴瘤, 增殖, 侵袭

Abstract: OBJECTIVE: To investigate the effect of celecoxib on proliferation, chemotherapy sensitivity and invasion of T cell lymphoma. METHODS: Jurkat and Hut78 cells were treated with celecoxib for 24, 48 and 72 h, and their proliferation activity and chemotherapy sensitivity were detected using the MTT method. In addition, apoptotic rates of the treated cells were analyzed using flow cytometry. Transwell chamber was used to investigate the invasion of cells which were treated with celecoxib for 48 h. Expression of P38, P65, Bcl-2, Bax, MDR1, MMP2 and MMP9 in treated cells were investigated using quantitative real-time PCR (qPCR) and Western blot. RESULTS: After treatment with celecoxib, growth of Jurkat and Hut78 cells was inhibited in a dose-and time-dependent manner, and their chemotherapy sensitivity was elevated. Consequently, the apoptotic rates of the treated cells were also higher than the control. The number of treated cells that passed through Transwell chamber was significantly less than control (P<0.01). The qPCR and Western blot analyses showed that expression of P65, Bax, MDR1, Bcl-2, MMP2 and MMP9 were all down-regulated, whereas P38 and Bax were up-regulated in the treated cells compared with control(P<0.05). CONCLUSION: Celecoxib has inhibitory effect on proliferation and invasion of T cell lymphoma. Therefore, it may have a broad prospect for clinical treatment of T cell lymphoma.

Key words: celecoxib, T cell lymphoma, proliferation, invasion

中图分类号:

R733.7

马鸣, 杨兴肖, 王雪晓, 刘丽华, 赵连梅, 杜彦艳, 单保恩. 塞来昔布对T细胞淋巴瘤细胞增殖及侵袭功能的影响[J]. 癌变·畸变·突变, 2016, 28(4): 255-261.

MA Ming, YANG Xingxiao, WANG Xuexiao, LIU Lihua, ZHAO Lianmei, DU Yanyan, SHAN Baoen. Effects of celecoxib on proliferation and invasion of T cell lymphoma[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(4): 255-261.

参考文献

[1] 李杰,薛丽英,王超,等. 塞来昔布对NB4细胞增殖凋亡及VEGF表达的影响[J]. 肿瘤防治杂志,2013,40(2):147-150.
[2] Rudner J,Elsaesser SJ,Jendrossek V,et al. Anti-apoptotic Bcl-2 fails to form efficient complexes with pro-apoptotic Bak to protect from Celecoxib-induced apoptosis[J].Biochem Pharmacol,2011,81(1):32-42.
[3] 张德庆,祝建红,陈卫昌. 塞来昔布联合5-FU抑制裸鼠结肠癌生长及其机制的探讨[J]. 中华肿瘤防治杂志,2013,20(1):15-20.
[4] 赵连梅,韩丽娜,商晓辉,等. 木鳖子醇提物对黑素瘤B16细胞增殖的抑制及其可能机制[J]. 中国肿瘤生物治疗杂志,2010,17(1):13-18.
[5] 王玲,李杰,张璟,等. 塞来昔布对人三阴性乳腺癌裸鼠体内白细胞介素6和白细胞介素8水平的影响[J]. 中国医科大学学报,2012,41(9):801-804.
[6] 范立侨,李勇,李巧霞,等. 塞来昔布联合氟尿嘧啶对MFC细胞615小鼠原位移植瘤COX2、Fas表达的影响及意义[J]. 肿瘤学杂志,2015,21(5):355-359.
[7] Brown MD,Sacks DB. Protein scaffolds in MAP kinase signalling[J]. Cell Signal,2009,21(4):462-469.
[8] 高克非,冯艳玲,黄永文,等. 三氧化二砷联合塞来昔布对卵巢癌细胞的增殖抑制和凋亡诱导作用[J]. 肿瘤,2014,34(7):602-608.
[9] Sareddy GR,Geeviman K,Ramulu C,et al. The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-kappaB pathway[J]. J Neurooncol,2012,106(1):99-109.
[10] 姚娟,翁亚光,严树涓,等. 肾母细胞瘤过表达基因对人骨肉瘤143B细胞增殖、凋亡和迁移的影响[J]. 肿瘤,2015,35(2):119-128.
[11] Cui XB,PangXL,Li S,et al. Elevated expression patterns and tight correlation of the PLCE1 and NF-κB signaling in Kazakh patients with esophageal carcinoma[J]. Med Oncol,2014,31(1):791.
[12] 杨雪,欧俐苹,王晓荣,等. PLC基因通过NF-B/p65途径抑制肾癌786-0细胞的增殖[J]. 第三军医大学学报,2014,36(19):2010-2015.
[13] Bo Liang,Xiao-Ling Guo,Jing Jin,et al. Glycyrrhizic acid inhibits apoptosis and fibrosis in carbon tetrachloride-induced rat liver injury[J]. World J Gastroenterol,2015,21(17):5271-5280.
[14] Ma B,Zhou PY,Ni W,et al. Inhibition of activin receptor-like kinase 5 induces matrix metallopeptidase9 expression and aggravates lipopolysaccharide-induced pulmonary injury in mice[J]. Eur Rev Med Pharmacol Sci,2013,17(8):1051-1059.
[15] Kao SJ,Su JL,Chen CK,et al. Osthole inhibits the invasive ability of human lung adenocarcinoma cells via suppression of NF-κB mediated matrix metallo proteinase-9 expression[J]. Toxicol Appl Pharmacol,2012,261(1):105-115.

塞来昔布对T细胞淋巴瘤细胞增殖及侵袭功能的影响

Effects of celecoxib on proliferation and invasion of T cell lymphoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	赵岩, 孙震晓. 二甲双胍抑制人MDA-MB-231细胞增殖及迁移的体外实验研究[J]. 癌变·畸变·突变, 2022, 34(1): 35-39.
[2]	王晓舟, 李洪石, 于溪, 魏宁, 王梓瑛, 赫丽杰. 青藤碱对HPV阳性宫颈癌SiHa细胞增殖和侵袭的影响[J]. 癌变·畸变·突变, 2021, 33(6): 442-445.
[3]	杨兴肖, 张雪原, 邹乃祎, 单保恩, 马鸣, 祝淑钗. 干扰HMGB1基因表达对食管鳞癌细胞侵袭迁移及放射敏感性的影响[J]. 癌变·畸变·突变, 2021, 33(5): 327-333.
[4]	王琛瑶, 梁百慧, 吴锦源, 唐梓涵, 许小文, 尹梓健, 丁雅琼, 方雄钊, 李栢芝, 文姝佚, 程转, 詹涵, 张粤烽, 王泫哲, 何仕龙, 张可洵, 刘雅骐, 周飞, 熊兴东, 白春英, 许丽艳, 李恩民. RAC1对恶性肿瘤的调控作用及其分子机制研究进展[J]. 癌变·畸变·突变, 2021, 33(5): 401-404.
[5]	黄晓华, 牛永东, 石刚刚. 核受体FXR激活对宫颈癌CaSki细胞增殖的抑制效应及其作用机制[J]. 癌变·畸变·突变, 2021, 33(4): 302-306.
[6]	郑珺文, 常晨, 郝佳洁, 蔡岩, 王明荣, 张钰. NEDD4在食管鳞癌中的表达及作用研究[J]. 癌变·畸变·突变, 2021, 33(3): 203-207,224.
[7]	张娜, 范志露, 杨荔艳, 常晨, 蔡岩, 郝佳洁, 王明荣. 食管鳞癌中SERPINB5表达降低的作用机制及其临床意义[J]. 癌变·畸变·突变, 2021, 33(2): 101-109.
[8]	方磊, 杨涛, 盛磊, 木塔力甫·艾买提, 齐鑫鑫, 艾尼娃尔·艾克木, 伊力亚尔·尼加提. 黑种草子总皂苷对人宫颈癌SiHa细胞生物学行为的影响[J]. 癌变·畸变·突变, 2021, 33(2): 143-148,152.
[9]	兰莉, 陈海丽, 徐蕾. RBMS3-AS3对宫颈癌细胞增殖、凋亡和侵袭的影响及作用机制[J]. 癌变·畸变·突变, 2020, 32(6): 438-443.
[10]	林凯煌, 蔡高阳, 刘新城. mTOR抑制剂AZD2014对肝癌细胞的增殖抑制作用及其机制研究[J]. 癌变·畸变·突变, 2020, 32(6): 448-451.
[11]	刘鹏, 白意晓. miR-29a对人胃癌细胞增殖、迁移的影响及其机制研究[J]. 癌变·畸变·突变, 2020, 32(6): 452-456,463.
[12]	许迎剑, 张航, 张建清. 细胞核受体RXRα在2,2',4,4'-四溴二苯醚神经毒性中的作用及其机制[J]. 癌变·畸变·突变, 2020, 32(5): 336-343,349.
[13]	戚玉竹, 刘静, 张国君. 核苷酸酶CD73在恶性肿瘤中作用和调控机制的研究进展[J]. 癌变·畸变·突变, 2020, 32(5): 398-401.
[14]	龙子, 樊隽澍, 吴光源, 王欣, 海春旭. 低剂量双酚A通过调控PPARγ致小鼠糖脂代谢紊乱的研究[J]. 癌变·畸变·突变, 2020, 32(4): 245-255.
[15]	陈琪, 钟茜, 岳文涛. RNA结合基元蛋白24通过调控HOTAIR表达抑制鼻咽癌细胞增殖[J]. 癌变·畸变·突变, 2020, 32(4): 275-280.